{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:18:22Z","timestamp":1790090302723,"version":"4.0.1"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.1001\/jamainternmed.2022.0045","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T11:37:42Z","timestamp":1646048262000},"page":"418","source":"Crossref","is-referenced-by-count":29,"title":["Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults"],"prefix":"10.1001","volume":"182","author":[{"given":"Juan P.","family":"Brito","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[{"name":"Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"National Clinician Scholars Program, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Hee","family":"Choi","sequence":"additional","affiliation":[{"name":"Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, White Oak, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Graham","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, White Oak, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandong","family":"Qiang","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, White Oak, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rantou","sequence":"additional","affiliation":[{"name":"Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, White Oak, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, White Oak, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, White Oak, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay D.","family":"Shah","sequence":"additional","affiliation":[{"name":"Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota"},{"name":"OptumLabs, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia J.","family":"Lipska","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"ioi220003r1","article-title":"Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice.","volume":"6","author":"Fuentes","year":"2018","journal-title":"Pharmacy (Basel)"},{"issue":"4","key":"ioi220003r2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S2213-8587(16)30276-5","article-title":"Levothyroxine overuse: time for an about face","volume":"5","author":"Rodriguez-Gutierrez","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"ioi220003r3","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1210\/jc.2018-02197","article-title":"Generic and brand-name thyroid hormone drug use among commercially insured and Medicare beneficiaries, 2007 through 2016.","volume":"104","author":"Ross","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"ioi220003r5","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999-2012.","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"ioi220003r6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement.","volume":"24","author":"Jonklaas","year":"2014","journal-title":"Thyroid"},{"issue":"7","key":"ioi220003r9","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system.","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"ioi220003r12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"ioi220003r13","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"2","key":"ioi220003r14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1210\/jc.2012-3125","article-title":"Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism.","volume":"98","author":"Carswell","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"ioi220003r15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17645","article-title":"Comparative effectiveness of generic vs brand-name levothyroxine in achieving normal thyrotropin levels.","volume":"3","author":"Brito","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"15","key":"ioi220003r16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/jama.1997.03540390068038","article-title":"Thyroid storm.","volume":"277","author":"Rennie","year":"1997","journal-title":"JAMA"},{"issue":"3","key":"ioi220003r17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1089\/105072503321582088","article-title":"Levothyroxine a new drug? since when? how could that be","volume":"13","author":"Hennessey","year":"2003","journal-title":"Thyroid"},{"issue":"15","key":"ioi220003r19","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jama.1997.03540390035032","article-title":"Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism.","volume":"277","author":"Dong","year":"1997","journal-title":"JAMA"},{"issue":"157","key":"ioi220003r20","first-page":"43535","article-title":"Prescription drug products; levothyroxine sodium.","volume":"62","author":"US Department of Health and Human Services","year":"1997","journal-title":"Fed Regist"},{"issue":"4","key":"ioi220003r22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/archinte.160.4.526","article-title":"The Colorado thyroid disease prevalence study.","volume":"160","author":"Canaris","year":"2000","journal-title":"Arch Intern Med"},{"key":"ioi220003r11","first-page":"348","volume-title":"Williams Textbook of Endocrinology","author":"Melmed","year":"2011","edition":"12th ed"},{"key":"ioi220003r18","author":"King","year":"1996"},{"key":"ioi220003r4","unstructured":"Endocrine Society. Bioequivalence of sodium levothyroxine: an Endocrine Society position statement. June 1, 2008. Accessed January 28, 2021. https:\/\/www.endocrine.org\/advocacy\/position-statements\/bioequivalence-of-sodium-levothyroxine"},{"key":"ioi220003r7","unstructured":"US Food and Drug Administration. Levothyroxine sodium product information. November 18, 2019. Accessed April 21, 2021. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/levothyroxine-sodium-product-information"},{"key":"ioi220003r8","unstructured":"US Food and Drug Administration. Real-world evidence from a narrow therapeutic index product (levothyroxine) reflects the therapeutic equivalence of generic drug products. November 19, 2020. Accessed April 21, 2021. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/real-world-evidence-narrow-therapeutic-index-product-levothyroxine-reflects-therapeutic-equivalence"},{"key":"ioi220003r10","unstructured":"Optum. Real world health care experiences from over 150 million unique individuals since 1993. 2015. Accessed February 2, 2021. https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/5302_Data_Assets_Chart_Sheet_ISPOR.pdf"},{"key":"ioi220003r21","unstructured":"Association for Accessible Medicines. 2018 generic drug access & savings in the U.S.: access in jeopardy. 2018. Accessed June 15, 2020. https:\/\/accessiblemeds.org\/sites\/default\/files\/2018_aam_generic_drug_access_and_savings_report.pdf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2789278\/jamainternal_brito_2022_oi_220003_1648847665.67134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T11:04:31Z","timestamp":1649070271000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2789278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2022.0045","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}